Panacea Pharmaceuticals, Inc. Presents Progress on Alzheimer's Disease Treatment Technology at AANP Annual Meeting.Business Editors & Health/Medical Writers BIOWIRE2K ROCKVILLE, Md.--(BUSINESS WIRE)--June 22, 2001 Panacea Pharmaceuticals, Inc. presented new findings today at the 77th Annual Meeting of the American Association of Neuropathologists American Association of Neuropathologists, Inc. was established in the 1930's as a professional and educational organization representing American neuropathologists. It was incorporated in the State of Pennsylvania in May 1960. in Chicago, Illinois that validates its proprietary Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. model. The presentation, entitled "Increased Oxidative Stress oxidative stress, n an imbalance of the prooxidant antioxidant ratio in which too few antioxidants are produced or ingested or too many oxidizing agents are produced. Involving Olfactory Epithelium olfactory epithelium n. Pseudostratified epithelium that contains olfactory, receptor, and nerve cells whose axons connect with the olfactory bulb of the brain. In Alzheimer's Disease," outlined changes in five key oxidative stress markers and the usefulness of cultured olfactory olfactory /ol·fac·to·ry/ (ol-fak´ter-e) pertaining to the sense of smell. ol·fac·to·ry adj. Of, relating to, or contributing to the sense of smell. neurons to provide an AD-specific oxidative stress model. The findings were also published in the Journal of Neuropathology neuropathology /neu·ro·pa·thol·o·gy/ (-pah-thol´ah-je) pathology of diseases of the nervous system. neu·ro·pa·thol·o·gy n. The study of diseases of the nervous system. and Experimental Neurology (Vol. 60, page 504, 2001). The data were presented by George Perry, Ph.D., Professor of Pathology and Neuroscience at Case Western Reserve University (CWRU CWRU Case Western Reserve University (Cleveland, OH) ) in Cleveland, Ohio. Dr. Perry is one of the prominent world experts in the field of Alzheimer's disease (AD) and is a pioneer in the area of oxidative stress in neurodegenerative diseases. He is the Company's Special Consultant for Alzheimer's Disease and a Collaborator at CWRU. The Company previously announced the signing of a Collaborative Research Agreement and a Licensing Agreement with Professor Perry at CWRU for the use of oxidative stress markers and proprietary models in screening drugs for neurodegenerative diseases, particularly AD. These agreements give the Company exclusive worldwide rights to the technology and establish a seamless working collaboration between the groups that grants the Company exclusive rights to all future developments through the collaboration. Dr. Perry stated, "This validated model allows us to utilize our extensive findings and understanding of these oxidative stress markers to screen compounds specifically aimed at protecting vulnerable neurons in the brain of Alzheimer's disease patients from damage while restoring normal function." "Our model is well suited for screening efforts aimed at discovering drug candidates that act as neuroprotectants," said Hossein A. Ghanbari, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Panacea and co-inventor of the technology. "These findings further demonstrate that we have developed an Alzheimer's-specific model that mimics vulnerable neurons in the brain." About Panacea Pharmaceuticals Panacea Pharmaceuticals, Inc. is a development stage biopharmaceutical company focused on utilizing functional genomics and proteomics to develop therapeutics and diagnostics for cancer, Alzheimer's disease, and Parkinson's disease. More information is available at www.PanaceaPharma.com, a web site developed by eiCommunications.com, Inc. (www.eiCommunications.com), which offers integrated communications and web development solutions for the Information Age. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion